Citations

Clear

789 citation(s) found for "Jenkins, RB".

Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma
Butz, Malinda L., Jenkins, Robert B. , Kitange, Gaspar J. , Kipp, Benjamin R. , Ida, Cristiane M. , Sarkaria, Jann N. , Giannini, Caterina

Mayo Clinic

American Journal of Clinical Pathology | May 6, 2017 | Volume: 148 | Issue: 4 | Pages: 296-307

10.1093/ajcp/aqx073 | PMID 28967952 Get It

Abstract Objectives To develop and evaluate a real-time methylation-specific polymerase chain reaction (RT-MSP) MGMT assay, with a particular focus on small biopsies and indeterminate testing results. Methods We assessed formalin-fixed paraffin-embedded glioblastoma or gliosarcoma specimens (n = 641). A test-validation group (n = 51) with previously obtained reference laboratory (RL) results was used to determine performance characteristics of the RT-MSP assay. An indeterminate (equivocal) category was established for cases that could not be clearly classified as positive or negative. Results Overall agreement of RT-MSP and RL results was 91% (41/45 nonindeterminate cases). Discordant cases were tested by pyrosequencing, and results were most concordant with RT-MSP. Among cases with limited amounts of tissue (n = 7), six yielded valid results by RT-MSP (all negative); the single invalid result consisted of a stereotactic biopsy specimen obtained 14 years prior. A subset of indeterminate cases obtained during clinical testing (n = 18/575 [3%]) was also evaluated by pyrosequencing and showed a heterogeneous pattern of methylation across the eight interrogated CpG sites. Conclusions The RT-MSP assay that we developed in-house is a robust clinical detection method for the heterogeneous process of MGMT promoter methylation in glioblastoma.
OS06.1 Genome-wide association study reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma
Melin, Beatrice , Kinnersley, Ben , Wrensch, Margaret , Jenkins, Robert B. , Ostrom, Quinn T. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S. , Bondy, Melissa L.

Mayo Clinic

Neuro-Oncology | April 27, 2017 | Volume: 19 | Issue: suppl_3 | Pages: iii10-iii11

10.1093/neuonc/nox036.035 Get It

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study
Chintakuntlawar, Ashish V. , Rumilla, Kandelaria M., Jenkins, Sarah M. , Foote, Robert L. , Kasperbauer, Jan L. , Ryder, Mabel , Alsidawi, Samer , Hilger, Crystal, Bible, Keith C. , Smith, Carin Y. , Morris, John C., Chintakuntlawar, Ashish V , Ryder, Mabel

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 19, 2017 | Volume: 102 | Issue: 6 | Pages: 1943-1950

10.1210/jc.2016-3756 | PMID 28324060 Get It

Multicenter Performance Assessment of Carba NP Test
Cunningham, Scott A. , Limbago, Brandi, Traczewski, Maria M., Anderson, Karen, Hackel, Meredith , Hindler, Janet A., Sahm, Dan, Alyanak, Efe, Lawsin, Adrian , Man, Tom J. B. de , Mandrekar, Jayawant N. , Jenkins, Stephen G., Humphries, Romney M. , Palavecino, Elizabeth , Patel, Robin , Vasoo, Shawn , Gulvik, Christopher A. , Schuetz, Audrey N. , Patel, Robin , Humphries, Romney , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | April 13, 2017 | Volume: 55 | Issue: 6 | Pages: 1954-1960

10.1128/jcm.00244-17 | PMID 28404676 Get It

ABSTRACT Eighty Gram-negative bacilli (54 Enterobacteriaceae and 26 nonfermenting Gram-negative bacilli) obtained from multiple institutions in the United States were distributed in a blinded manner to seven testing laboratories to compare their performance of a test for detection of carbapenemase production, the Carba NP test. The Carba NP test was performed by all laboratories, following the Clinical and Laboratory Standards Institute (CLSI) procedure. Site-versus-site comparisons demonstrated a high level of consistency for the Carba NP assay, with just 3/21 site comparisons yielding a difference in sensitivity ( P < 0.05). Previously described limitations with bla OXA-48-like carbapenemases and bla OXA carbapenemases associated with Acinetobacter baumannii were noted. Based on these data, we demonstrate that the Carba NP test, when implemented with the standardized CLSI methodology, provides reproducible results across multiple sites for detection of carbapenemases.
Comparison of Whole-Genome Sequencing Methods for Analysis of Three Methicillin-Resistant Staphylococcus aureus Outbreaks
Cunningham, Scott A. , Jeraldo, Patricio , Quest, Daniel, Boxrud, Dave, Jenkins, Gregory D. , Drucker, Travis, Nelson, Heidi , Patel, Robin , Chia, Nicholas , Jeraldo, Patricio R , Quest, Daniel J, Drucker, Travis M, Chia, Nicholas , Johnson, Julie A. , Taylor, Angela , Chen, Jun , Patel, Robin , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | April 13, 2017 | Volume: 55 | Issue: 6 | Pages: 1946-1953

10.1128/jcm.00029-17 | PMID 28404677 Get It

ABSTRACT Whole-genome sequencing (WGS) can provide excellent resolution in global and local epidemiological investigations of Staphylococcus aureus outbreaks. A variety of sequencing approaches and analytical tools have been used; it is not clear which is ideal. We compared two WGS strategies and two analytical approaches to the standard method of SmaI restriction digestion pulsed-field gel electrophoresis (PFGE) for typing S. aureus . Forty-two S. aureus isolates from three outbreaks and 12 reference isolates were studied. Near-complete genomes, assembled de novo with paired-end and long-mate-pair (8 kb) libraries were first assembled and analyzed utilizing an in-house assembly and analytical informatics pipeline. In addition, paired-end data were assembled and analyzed using a commercial software package. Single nucleotide variant (SNP) analysis was performed using the in-house pipeline. Two assembly strategies were used to generate core genome multilocus sequence typing (cgMLST) data. First, the near-complete genome data generated with the in-house pipeline were imported into the commercial software and used to perform cgMLST analysis. Second, the commercial software was used to assemble paired-end data, and resolved assemblies were used to perform cgMLST. Similar isolate clustering was observed using SNP calling and cgMLST, regardless of data assembly strategy. All methods provided more discrimination between outbreaks than did PFGE. Overall, all of the evaluated WGS strategies yielded statistically similar results for S. aureus typing.
Bostwick, David G., Lieber, Michael M., Jenkins, Robert B. , Qian, J.

Mayo Clinic

The Japanese Journal of Urology | April 6, 2017 | Volume: 89 | Issue: 2 | Pages: 267

10.5980/jpnjurol.89.267_2 Get It

Lieber, Michael M., Jenkins, Robert B.

Mayo Clinic

The Japanese Journal of Urology | April 6, 2017 | Volume: 87 | Issue: 2 | Pages: 283

10.5980/jpnjurol.87.283_1 Get It

CAHPS Cancer Care Survey: Development, testing, and final content of a survey of patient experience with cancer care.
Evensen, Christian, Yost, Kathleen J. , Keller, San, Cowans, Tamika, Frentzel, Elizabeth , Jenkins, Sarah M. , Egginton, Jason S. , Arora, Neeraj, Garfinkel, Steven

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 35 | Issue: 8_suppl | Pages: 227-227

10.1200/jco.2017.35.8_suppl.227 Get It

227 Background: The objective of this work was to develop a reliable and valid survey measuring aspects of cancer care important to patients to be used in both inpatient and outpatient settings, and that allows comparisons of patient experiences across treatment centers and treatment modalities (medical oncology, radiation, surgery). Other objectives included testing various modes of data collection and developing a standardized sampling methodology based on ICD diagnosis and procedure codes. Methods: We conducted focus groups with patients who had received cancer treatment and with family members of cancer patients. We convened a panel of experts representing quality improvement, oncology, shared decision-making, patient safety, and patient advocacy to obtain feedback on the development of the survey. We interviewed stakeholder groups representing oncology associations to obtain feedback on focal provider, attribution and sampling. We then conducted a field test of the survey among six cancer centers around the country, conducted psychometric analyses, revised the survey, conducted a second field test among four community oncology practices in CA, re-analyzed the data, and finalized the survey. Results: Final survey content was determined using results of the formative research, psychometric analyses, and input from the CAHPS Consortium. The core survey includes 56 questions, 23 of which map to eight composites: Provider Communication, Enabling Patient Self-management, Team Available to Provide Information, Access to Care, Care Coordination, and Office Staff. Supplemental item sets include seven items assessing Shared Decision Making, four items measuring Keeping Patients Informed, and two additional Access to Care items. Mail-only, mail-telephone mixed-mode, and web-mail mixed-mode are recommended methods of data collection. The survey and all recruiting materials are available in English and Spanish. Conclusions: The CAHPS Cancer Care Survey is a rigorously developed, well-tested, reliable and valid survey of patient experiences with their cancer care. The survey and supporting materials are available free of charge on the CAHPS website (www.ahrq.gov/cahps).
Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial
Miller, Dylan V. , Jenkins, Robert B. , Lingle, Wilma L., Davidson, Nancy E. , Martino, Silvana, Dakhil, Shaker R. , Perez, Edith A. , Kaufman, Peter A.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 568-568

10.1200/jco.2004.22.90140.568 Get It

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial
Perez, Edith A. , Davidson, Nancy E. , Martino, Silvana, Lingle, Wilma L., Flynn, Patrick J. , Visscher, Daniel W., Jenkins, Robert B. , Suman, Vera J. , Kaufman, Peter A. , Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 567-567

10.1200/jco.2004.22.90140.567 Get It